» Articles » PMID: 35215248

Laboratory Selection of Trypanosomatid Pathogens for Drug Resistance

Overview
Publisher MDPI
Specialty Chemistry
Date 2022 Feb 26
PMID 35215248
Authors
Affiliations
Soon will be listed here.
Abstract

The selection of parasites for drug resistance in the laboratory is an approach frequently used to investigate the mode of drug action, estimate the risk of emergence of drug resistance, or develop molecular markers for drug resistance. Here, we focused on the How rather than the Why of laboratory selection, discussing different experimental set-ups based on research examples with , , and spp. The trypanosomatids are particularly well-suited to illustrate different strategies of selecting for drug resistance, since it was with African trypanosomes that Paul Ehrlich performed such an experiment for the first time, more than a century ago. While breakthroughs in reverse genetics and genome editing have greatly facilitated the identification and validation of candidate resistance mutations in the trypanosomatids, the forward selection of drug-resistant mutants still relies on standard in vivo models and in vitro culture systems. Critical questions are: is selection for drug resistance performed in vivo or in vitro? With the mammalian or with the insect stages of the parasites? Under steady pressure or by sudden shock? Is a mutagen used? While there is no bona fide best approach, we think that a methodical consideration of these questions provides a helpful framework for selection of parasites for drug resistance in the laboratory.

Citing Articles

STIB980: A TcI Strain for Drug Discovery and Reverse Genetics.

Fesser A, Beilstein S, Kaiser M, Schmidt R, Maser P Pathogens. 2023; 12(10).

PMID: 37887733 PMC: 10610277. DOI: 10.3390/pathogens12101217.

References
1.
De Koning H . Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol Pharmacol. 2001; 59(3):586-92. DOI: 10.1124/mol.59.3.586. View

2.
Terstappen G, Schlupen C, Raggiaschi R, Gaviraghi G . Target deconvolution strategies in drug discovery. Nat Rev Drug Discov. 2007; 6(11):891-903. DOI: 10.1038/nrd2410. View

3.
Shaw S, Knusel S, Hoenner S, Roditi I . A transient CRISPR/Cas9 expression system for genome editing in Trypanosoma brucei. BMC Res Notes. 2020; 13(1):268. PMC: 7268226. DOI: 10.1186/s13104-020-05089-z. View

4.
Campos M, Phelan J, Francisco A, Taylor M, Lewis M, Pain A . Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole. Sci Rep. 2017; 7(1):14407. PMC: 5663738. DOI: 10.1038/s41598-017-14986-6. View

5.
Yang P, Wang M, Liu K, Ngai M, Sheriff O, Lear M . Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent. Chemistry. 2012; 18(27):8403-13. DOI: 10.1002/chem.201200482. View